Herpes Simplex Clinical Trial
Official title:
Polymorphism of the Herpes Simplex Virus Receptor
Verified date | April 13, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will examine the structure of the receptor molecule for the herpes simplex virus
(HSV) and determine if the receptor's structure is related to susceptibility to infection
with the virus. There are two types of herpes virus-HSV-1 and HSV-2. HSV-1 commonly causes
cold sores, and HSV-2 usually causes genital herpes. The herpes virus enters (infects) cells
through protein molecules on the cell's surface. This study will explore possible differences
between the structure of the HSV receptor molecule in different people to understand better
how infection occurs. The study will also look at proteins on white blood cells (Fc
receptors, cytokines and mannose binding protein) that may influence the risk of infection
with HSV. Information from this study may lead to new treatments to prevent HSV infection.
People 18 years of age and older who are infected with HSV and people who are not infected
with the virus may be eligible for this study. Participants will have blood drawn to confirm
whether or not they have been infected with the virus. The blood sample will also be used to
study the genes for the HSV receptor, Fc receptors, cytokines, mannose binding protein and
related proteins on the white blood cells. No more than 40 milliliters (8 teaspoons) of blood
will be drawn.
Participants who are found to have antibodies to HSV-2 will be offered counseling and advice
on practicing safe sex techniques to help prevent sexually transmitted diseases, including
HSV-2 infection.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 13, 2010 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: HSV-2 Seronegative Patients: Individuals known or likely to be seronegative for HSV-2 will be recruited. All racial, gender, and ethnic groups will be considered. Adult volunteers at least 18 years of age. Volunteers who were seronegative for HSV-2 (regardless of HSV-1 serology) confirmed by Western blot. Volunteers are willing to allow investigators to store their blood. HSV-2 seropositive patients (with or without symptoms): All racial and ethnic groups will be considered. Volunteers who were seropositive for HSV-2 (regardless of HSV-1 serology) confirmed by Western blot. Volunteers are willing to allow investigators to store their blood. Normal Controls: To determine the frequency of a genetic polymorphism in a population that has not had prior screening for HSV, blood may be obtained from normal control blood donors. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996 May 10;272(5263):872-7. — View Citation
Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem. 1997 May 30;272(22):14029-32. — View Citation
Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell. 1996 Nov 1;87(3):427-36. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05468619 -
Neonatal Phase 1 Valacyclovir Study
|
Phase 1 | |
Withdrawn |
NCT02349828 -
Antiviral Prophylaxis in a Burn Population
|
Phase 2/Phase 3 | |
Recruiting |
NCT01176409 -
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
|
Phase 3 | |
Completed |
NCT04664127 -
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
|
||
Completed |
NCT00448227 -
Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection
|
Phase 2 | |
Completed |
NCT00000139 -
Herpetic Eye Disease Study (HEDS) II
|
Phase 3 | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT02209324 -
Open-label Study of ASP2151 in Herpes Simplex Patients
|
Phase 3 | |
Completed |
NCT00855309 -
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
|
Phase 3 | |
Completed |
NCT01602562 -
Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
|
Phase 3 | |
Completed |
NCT00973466 -
Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients
|
N/A | |
Completed |
NCT00698893 -
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
|
Phase 1 | |
Active, not recruiting |
NCT05298254 -
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
|
Phase 1/Phase 2 | |
Recruiting |
NCT03178747 -
Tzanck Smear With Methylene Blue Stain for Herpes
|
Phase 3 | |
Completed |
NCT00164424 -
Episodic Acyclovir Therapy for Genital Ulcers
|
Phase 2/Phase 3 | |
Completed |
NCT00161434 -
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
|
Phase 4 | |
Terminated |
NCT04762511 -
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
|
Phase 1 | |
Completed |
NCT00699764 -
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
|
Phase 3 | |
Recruiting |
NCT04065971 -
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
|
Phase 4 | |
Active, not recruiting |
NCT00005663 -
A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients
|
Phase 3 |